Man Group
BCAB icon

Man Group’s BioAtla BCAB Stock Holding History

Man Group’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-752
Closed -$113K – 1921
2023
Q2 		$113K Buy
+752
New +$129K ﹤0.01% 1875
2023
Q1 		– Sell
-292
Closed -$52.6K – 1749
2022
Q4 		$120K Buy
292
+59
+25% +$24.5K ﹤0.01% 1882
2022
Q3 		$90K Buy
+233
New +$76.3K ﹤0.01% 1863
2022
Q2 		– Sell
-260
Closed -$41.4K – 1941
2022
Q1 		$65K Buy
+260
New +$109K ﹤0.01% 2100

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Man Group's BCAB Position: Q3 2023 in Review

Man Group sold out of BioAtla (BCAB) in Q3 2023, closing a stake of 752 shares — an estimated $113K sold.

Man Group first reported a position in BCAB in Q1 2022 and held it in 4 quarters. The position peaked at $120K in Q4 2022. 82 funds tracked by Wall St. Rank hold BCAB as of Q3 2023.

  • Man Group reported no remaining BioAtla position as of Q3 2023 after selling out during the quarter.
  • Man Group sold 752 BioAtla shares in Q3 2023, an estimated $113K.
  • Man Group first reported a position in BioAtla in Q1 2022 and held it in 4 quarters.
  • Man Group's BioAtla position peaked at $120K in Q4 2022.
  • 82 funds tracked by Wall St. Rank held BioAtla as of Q3 2023.

Based on Man Group's 13F filing for Q3 2023, filed 14 Nov 2023.